...
首页> 外文期刊>Biological chemistry >Interplay between reversible phosphorylation and irreversible ADP-ribosylation of eukaryotic translation elongation factor 2
【24h】

Interplay between reversible phosphorylation and irreversible ADP-ribosylation of eukaryotic translation elongation factor 2

机译:可逆磷酸化与真核转换伸长系数2的不可逆磷酸化与不可逆ADP-核糖化的相互作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The functionality of eukaryotic translation elongation factor 2 (eEF2) is modulated by phosphorylation, eEF2 is simultaneously the molecular target of ADP-ribosylating toxins. We analyzed the interplay between phosphorylation and diphthamide-dependent ADP-ribosylation. Phosphorylation does not require diphthamide, eEF2 without it still becomes phosphorylated. ADP-ribosylation not only modifies the H715 diphthamide but also inhibits phosphorylation of S595 located in proximity to H715, and stimulates phosphorylation of T56. S595 can be phosphorylated by CDK2 and CDK1 which affects EEF2K-mediated T56-phosphorylation. Thus, ADP-ribosylation and S595-phosphorylation by kinases occur within the same vicinity and both trigger T56-phosphorylation. Diphthamide is surface-accessible permitting access to ADP-ribosylating enzymes, the adjacent S595 side chain extends into the interior. This orientation is incompatible with phosphorylation, neither allowing kinase access nor phosphate attachment. S595 phosphorylation must therefore be accompanied by structural alterations affecting the interface to ADP-ribosylating toxins. In agreement with that, replacement of S595 with Ala, Glu or Asp prevents ADP-ribosylation. Phosphorylation (starvation) as well as ADP-ribosylation (toxins) inhibit protein synthesis, both affect the S595/H715 region of eEF2, both trigger T57-phosphorylation eliciting similar transcriptional responses. Phosphorylation is short lived while ADP-ribosylation is stable. Thus, phosphorylation of the S595/H715 ‘modifier region’ triggers transient interruption of translation while ADP-ribosylation arrests irreversibly.
机译:通过磷酸化调节真核转换伸长系数2(EEF2)的功能,EEF2同时为ADP-核糖基毒素的分子靶标。我们分析了磷酸化与二谷物依赖性ADP-核糖化之间的相互作用。磷酸化不需要二高酰胺,EEF2没有它仍然变得磷酸化。 ADP-核糖基化不仅改变了H715二核苷酸,而且还抑制位于H715邻近的S595的磷酸化,并刺激T56的磷酸化。 S595可以通过CDK2和CDK1磷酸化,所述CDK2和CDK1影响EEF2K介导的T56-磷酸化。因此,通过激酶在相同的附近和触发T56-磷酸化内发生Adp-核糖基化和S595-磷酸化。双硫氧化物是表面可接近的允许进入ADP-核糖基化酶,相邻的S595侧链延伸到内部。这种取向与磷酸化不相容,既不允许激酶存取也不磷酸盐附着。因此,S595磷酸化必须伴有影响ADP-核糖基化毒素的界面的结构改变。同意,用ALA,GLU或ASP更换S595,可防止ADP-核糖化。磷酸化(饥饿)以及ADP-核糖基化(毒素)抑制蛋白质合成,两者都影响EEF2的S595 / H715区域,触发T57-磷酸化引起类似的转录反应。磷酸化短寿命,而ADP-核糖基化是稳定的。因此,S595 / H715'改性剂区域'的磷酸化触发翻译的瞬态中断,而ADP-核糖基化被不可逆地阻止。

著录项

  • 来源
    《Biological chemistry》 |2019年第4期|共12页
  • 作者单位

    Roche Pharma Research and Early Development Discovery Oncology Roche Innovation Center Munich;

    Roche Pharma Research and Early Development Large Molecule Research Roche Innovation Center;

    Roche Pharma Research and Early Development Large Molecule Research Roche Innovation Center;

    Roche Pharma Research and Early Development Pharmaceutical Sciences- Bioinformatics Roche;

    Roche Pharma Research and Early Development Discovery Oncology Roche Innovation Center Munich;

    Roche Pharma Research and Early Development Large Molecule Research Roche Innovation Center;

    Roche Pharma Research and Early Development Discovery Oncology Roche Innovation Center Munich;

    Laboratory of Molecular Biology Center for Cancer Research National Cancer Institute National;

    Laboratory of Molecular Biology Center for Cancer Research National Cancer Institute National;

    Roche Pharma Research and Early Development Large Molecule Research Roche Innovation Center;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物化学;
  • 关键词

    amino acid deprivation; apoptosis; diphthamide; diphtheria toxin; Pseudomonas exotoxin targeted therapy;

    机译:氨基酸剥夺;细胞凋亡;二华酰胺;白喉毒素;伪霉素Exotoxin靶向治疗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号